Phase I Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib, in Advanced Solid Tumors
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
General Information
NCT#: NCT02549937
Study ID: 2015-012-00US1
Trial Phase: Phase I
Trial Sponsor: Hutchison MediPharma
Therapies Used in This Trial: Surufatinib